Filing Details

Accession Number:
0001615219-16-000177
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-05-23 11:42:10
Reporting Period:
2016-05-19
Filing Date:
2016-05-23
Accepted Time:
2016-05-23 11:42:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1615219 Flex Pharma Inc. FLKS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1291961 H Christoph Westphal C/O Flex Pharma, Inc.
800 Boylston Street
Boston MA 02199
President And Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-05-19 6,914 $11.00 3,076,627 No 4 P Indirect See notes
Common Stock Acquisiton 2016-05-20 1,000 $11.44 3,077,627 No 4 P Indirect See notes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See notes
No 4 P Indirect See notes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,925,248 Direct
Footnotes
  1. The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $10.88 to $11.05. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
  2. On May 19, 2016, Longwood Fund III, L.P. ("Longwood Fund III") purchased 6,914 shares of common stock of the Issuer (the "Common Shares"). Following such purchase, Longwood Fund III owned 379,363 Common Shares and Longwood Fund II, L.P. ("Longwood Fund II") owned 2,697,264 Common Shares.
  3. Longwood Fund II GP, LLC is the ultimate General Partner of Longwood Fund II and Longwood Fund III GP, LLC is the ultimate General Partner of Longwood Fund III. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund II GP, LLC and Longwood Fund III GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the Issuer's securities held by Longwood Fund II and Longwood Fund III (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.
  4. The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $11.18 to $11.70. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
  5. On May 20, 2016, Longwood Fund III purchased 1,000 Common Shares. Following such purchase, Longwood Fund III owned 380,363 Common Shares and Longwood Fund II owned 2,697,264 Common Shares.